PT Soho Global Health Tbk (SOHO) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of PT Soho Global Health Tbk IDR 970, price IDR 1,430, upside -32.2%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PT Soho Global Health Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
PT Soho Global Health Tbk, together with its subsidiaires, operates as a healthcare company in Indonesia. It operates through Distributions, Consumer Health, Alliance, and Others segments.
Show more
PT Soho Global Health Tbk, together with its subsidiaires, operates as a healthcare company in Indonesia. It operates through Distributions, Consumer Health, Alliance, and Others segments. The company researches, develops, and markets specialty-focused medicines for use in the therapeutic areas of immunomodulator, respiratory, inflammation, and liver diseases; offers nonprescription brand products to treat and prevent diseases; and distribution and logistics services. It also offers body defense, stamina and vitality, brain nutrient, eye health, skin care, weight management, and wellness products; sells and markets medical devices and medical equipment products in the areas of wound care, hospital general care, surgery, orthopedics, and in-vitro diagnostics; and provides product registration, marketing intelligence, sales, and marketing support services. In addition, it provides contract manufacturing services for various dosage forms. The company was founded in 1946 and is headquartered in Jakarta, Indonesia.
Stock analysis
PT Soho Global Health Tbk (SOHO) currently trades at 1,430 IDR, while our model-based Fair Value estimate is 969.59 IDR, implying the stock looks roughly 47.5% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 1,178 IDR per share, and 1 of the 26 models we run sit above the 1,430 IDR price.
Bear case: the Asset-Based group reads lowest at 136.36 IDR, and 25 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 690.83 IDR (bear) to 1,241 IDR (bull), the price of 1,430 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
PT Soho Global Health Tbk reported revenue of 10.8T IDR in FY2025 versus 7.1T IDR in FY2021, a compound +11.1%/yr. Reported net income was 600B IDR in FY2025, compounding +2.2%/yr from FY2021.
Key figures
Market cap 18.1T IDR (≈ $1.8B) · P/E ratio 27.5 · P/S ratio 1.53 · EPS (TTM) 51.96 IDR · Dividend yield 2.0% · Net margin 5.6% · Return on equity 23.4% · Return on assets (EBIT) 11.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 104% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −32%, SOHO screens richer than that median.
Fair Value models
Bear 690.83 IDRFair Value 969.59 IDRBull 1,241 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (38.01 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.6%
Dividend (yield on the price)2.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 7%
2025 sits 62% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +14.1% a year for the price.
Compare PT Soho Global Health Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−32% · Below median
Profitability
Return on equity (TTM)23% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)6% · Top 25%
Operating margin (TTM)9% · Top 25%
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)2.0% · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (TTM)27.5× · Priciest 25%
P/B7.03× · Priciest 25%
P/S (TTM)1.69× · Priciest 25%
P/FCF0.0× · Cheapest 25%
EV/EBITDA20.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 42
FUTURE (revenue growth)0· sector 17
PAST (return on equity)93· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)40· sector 59
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PT Soho Global Health Tbk Fair Value". https://www.fairvalue-calculator.com/stock/SOHO
Frequently asked questions
Is PT Soho Global Health Tbk (SOHO) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 969.59 IDR versus a price of 1,430 IDR, about −32% upside (overvalued).
What is the fair value of SOHO?
Our model-based fair value for PT Soho Global Health Tbk is 969.59 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,430 IDR.
What is the quality score of SOHO?
PT Soho Global Health Tbk has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Soho Global Health Tbk (SOHO)?
Our model-based price target is the fair value of 969.59 IDR (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 690.83 IDR, optimistic scenario 1,241 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Soho Global Health Tbk stock forecast for 2026?
Our models put fair value at 969.59 IDR, about −32% upside versus a price of 1,430 IDR (overvalued). Cautious scenario 690.83 IDR, optimistic scenario 1,241 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Soho Global Health Tbk (SOHO)?
PT Soho Global Health Tbk reported trailing-twelve-month revenue of about 10.7T IDR (latest available figure, as of Sep 24, 2026).
Does PT Soho Global Health Tbk pay a dividend?
PT Soho Global Health Tbk currently shows a dividend yield of about 1.98% relative to its recent price (as of Sep 24, 2026).
What growth is priced into PT Soho Global Health Tbk (SOHO)?
For today's price to be fair in a discounted-cash-flow model, PT Soho Global Health Tbk would have to grow free cash flow by +17.1 % per year for five years (discount rate 13.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SOHO use?
Our models discount PT Soho Global Health Tbk at 13.0 %: a base by market capitalisation (small), damped by beta 0.87, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PT Soho Global Health Tbk that is +17.1 % per year a year over ten years, using the same discount rate (13.0 %) and the same formula as our fair value.
How much growth has PT Soho Global Health Tbk (SOHO) delivered so far?
Over the past 5 years revenue at PT Soho Global Health Tbk grew +11.8 % a year. The price currently implies +17.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PT Soho Global Health Tbk (SOHO) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into PT Soho Global Health Tbk (+17.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PT Soho Global Health Tbk (SOHO)?
The free-cash-flow yield on the price is 4.74 %: that much free cash flow PT Soho Global Health Tbk produces per unit of market value. When it exceeds the discount rate of our models (13.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PT Soho Global Health Tbk (SOHO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Soho Global Health Tbk it is 969.59 IDR per share (as of Sep 24, 2026), against a price of 1,430 IDR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is PT Soho Global Health Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SOHO trades above its calculated fair value: price 1,430 IDR, fair value 969.59 IDR, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOHO?
No. The price is what the market pays today (1,430 IDR); the fair value is what the company's own numbers justify (969.59 IDR). For PT Soho Global Health Tbk the two are 460.41 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Soho Global Health Tbk worth?
The market values PT Soho Global Health Tbk at about 18.1T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 1,430 IDR; our models calculate a fair value of 969.59 IDR per share.
What do the bullish and bearish scenarios say about SOHO?
Our models span a range for PT Soho Global Health Tbk: cautious scenario 690.83 IDR, base 969.59 IDR, optimistic 1,241 IDR per share (as of Sep 24, 2026, price 1,430 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SOHO?
PT Soho Global Health Tbk trades at a price-to-earnings ratio of 27.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 969.59 IDR is built from several models across several years. Other multiples: P/B 7.0, P/S 1.7, EV/EBITDA 20.2.
How solid is the balance sheet of PT Soho Global Health Tbk (SOHO)?
Balance-sheet figures for PT Soho Global Health Tbk (as of Sep 24, 2026): return on equity 23.4%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is SOHO from its 52-week high?
PT Soho Global Health Tbk trades at 1,430 IDR, about 57% below its 52-week high of 3,291 IDR and 104% above the low of 699.91 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 969.59 IDR is for.
Which stocks are comparable to PT Soho Global Health Tbk?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Soho Global Health Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 1,430 IDR, calculated fair value 969.59 IDR (−32%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOHO calculated?
We run PT Soho Global Health Tbk through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 969.59 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. PT Soho Global Health Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Soho Global Health Tbk (SOHO)?
The closing price on Sep 23, 2026 was 1,430 IDR. Our model-based fair value is 969.59 IDR, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Soho Global Health Tbk right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (1,241 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of PT Soho Global Health Tbk
How large is the market capitalisation of PT Soho Global Health Tbk (SOHO)?
The market capitalisation of PT Soho Global Health Tbk is 18.1T IDR (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Soho Global Health Tbk (SOHO)?
The price-to-sales ratio of PT Soho Global Health Tbk is 1.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PT Soho Global Health Tbk (SOHO)?
Earnings per share at PT Soho Global Health Tbk are 51.96 IDR (price ÷ EPS = P/E 27.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PT Soho Global Health Tbk (SOHO)?
The dividend yield of PT Soho Global Health Tbk is 2.0% (payout 54.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Soho Global Health Tbk (SOHO)?
The net margin of PT Soho Global Health Tbk is 5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Soho Global Health Tbk (SOHO)?
The return on equity (ROE) of PT Soho Global Health Tbk is 23.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Soho Global Health Tbk (SOHO)?
On an EBIT basis the return on assets of PT Soho Global Health Tbk is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Soho Global Health Tbk (SOHO)?
The operating margin of PT Soho Global Health Tbk is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Soho Global Health Tbk (SOHO)?
Revenue at PT Soho Global Health Tbk is growing −1.3% versus a year earlier (3y avg +13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Soho Global Health Tbk (SOHO)?
Earnings per share at PT Soho Global Health Tbk are growing +42.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does PT Soho Global Health Tbk (SOHO) hold?
PT Soho Global Health Tbk holds more cash than debt, 1.1T IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PT Soho Global Health Tbk in the live analysis
One click puts PT Soho Global Health Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
